Genentech's Avastin Passes Key Safety Test
05/16/08 - 07:33 AM EDT
Elizabeth Trotta
"If the addition of Avastin to mFOLFOX6 in the adjuvant colon cancer setting demonstrates a significant disease-free survival benefit, it would represent an upside to our current Avastin Estimates," wrote UBS analyst Maged Shenouda, who has a buy rating and a $92 price target on the stock, in a note to investors.
Efficacy data for this trial aren't yet available. See senior columnist Adam Feuerstein's preview to ASCO abstracts for a guide to more data from biotechnology companies, such as ImClone(IMCL Quote - Cramer on IMCL - Stock Picks), Amgen(AMGN Quote - Cramer on AMGN - Stock Picks) and Celgene(CELG Quote - Cramer on CELG - Stock Picks) that were also released late Thursday.
Featured Photo Galleries
Sign up for our FREE newsletters now.
See All
Sponsored by:
RSS
